XBiotech (XBIT) Liabilities and Shareholders Equity (2014 - 2026)
XBiotech (XBIT) posted quarterly Liabilities and Shareholders Equity of $150.1 million for Q4 2025, down 24.62% year-over-year from $199.1 million in Q4 2024, and down 12.96% quarter-over-quarter from $172.4 million in Q3 2025.
XBiotech (XBIT) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
XBiotech's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $150.1 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 24.62% year-over-year to $150.1 million; the TTM figure through Dec 2025 stood at $683.1 million (down 19.86% YoY), while the FY2025 annual figure was $150.1 million, down 24.62% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $150.1 million, down from $172.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $355.9 million in Q1 2021, with the low at $150.1 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $232.4 million (2023), against an average of $238.4 million.
- The sharpest annual moves came in 2021 and 2022: Liabilities and Shareholders Equity declined 0.68% in 2021, then dropped 24.72% in 2022.
- XBiotech's Liabilities and Shareholders Equity stood at $275.2 million in 2021, then fell by 10.57% to $246.1 million in 2022, then fell by 7.92% to $226.6 million in 2023, then decreased by 12.14% to $199.1 million in 2024, then retreated by 24.62% to $150.1 million in 2025.
- Business Quant data shows XBIT's Liabilities and Shareholders Equity at $150.1 million in Q4 2025, $172.4 million in Q3 2025, and $178.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | XBiotech | 69.51 Mn | 69.51 Mn | - | 133.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.65 Mn |
| Dec 31, 2025 | 150.08 Mn |
| Sep 30, 2025 | 172.42 Mn |
| Jun 30, 2025 | 178.68 Mn |
| Mar 31, 2025 | 181.86 Mn |
| Dec 31, 2024 | 199.09 Mn |
| Sep 30, 2024 | 209.85 Mn |
| Jun 30, 2024 | 215.56 Mn |
| Mar 31, 2024 | 227.86 Mn |
| Dec 31, 2023 | 226.62 Mn |
| Sep 30, 2023 | 229.60 Mn |
| Jun 30, 2023 | 235.14 Mn |
| Mar 31, 2023 | 242.12 Mn |
| Dec 31, 2022 | 246.10 Mn |
| Sep 30, 2022 | 250.83 Mn |
| Jun 30, 2022 | 266.46 Mn |
| Mar 31, 2022 | 270.80 Mn |
| Dec 31, 2021 | 275.18 Mn |
| Sep 30, 2021 | 279.52 Mn |
| Jun 30, 2021 | 353.96 Mn |